Healthcare / BiotechnologyTokyo
$48.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-6.7B · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$19.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-166.6%
↓Gross Margin
36.7%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+135.3%
FCF CAGR
—
FCF margin
-659.5%
FCF / Net income
1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $874.1M · net income $-5.12B · FCF $-5.76B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $874.1M | $874.1M | $643.6M | $153.0M | $67.1M |
| Net Income | $-5.12B | $-5.12B | $-28.13B | $-7.44B | $-14.71B |
| EBITDA | $-5.09B | $-5.09B | $-5.74B | $-8.86B | $-13.41B |
| EPS | -14.44 | -14.44 | -119.53 | -39.29 | -94.29 |
| Gross Margin | 36.7% | 36.7% | 38.5% | 12.7% | -40.0% |
| Operating Margin | -588.6% | -588.6% | -1415.3% | -7822.7% | -24331.6% |
| Net Margin | -586.1% | -586.1% | -4370.3% | -4861.7% | -21942.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.13 | 0.01 | 0.04 |
| Current Ratio | 1.97 | 1.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.76B | $-5.76B | $-6.69B | $-8.84B | $-11.23B |
| Returns | |||||
| ROE | -166.6% | -166.6% | -1304.3% | -28.5% | -48.4% |
| Valuation | |||||
| P/B | 5.54 | 5.54 | 5.78 | 0.54 | 0.62 |
| Growth & Yield | |||||
| Revenue Growth | 35.8% | 35.8% | 320.7% | 128.1% | — |
| EPS Growth | 87.9% | 87.9% | -204.2% | 58.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-119.53 → -14.44
Residual
-25.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.